ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F16%3A43911347" target="_blank" >RIV/00216208:11120/16:43911347 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.ijcard.2016.04.016" target="_blank" >http://dx.doi.org/10.1016/j.ijcard.2016.04.016</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijcard.2016.04.016" target="_blank" >10.1016/j.ijcard.2016.04.016</a>

Result language
angličtina
Original language name
ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison
Original language description
Complete 2-year clinical follow-up was obtained in 97.2% of all the patients. Following current guidelines, DAPT was withdrawn at 12 months, unless it was clinically indicated (i.e. patient with repeat revascularization within the first year). This report, summarizing the first long-term outcomes of BVS in STEMI patients, shows that at 2-year follow-up, beyond the usual prescribed period of DAPT, no statistical differences seem to be present between BVS and EES in STEMI patients in terms of DOCE. In this sense, our data are in line with the recent observation of non-inferior vascular healing at 6-month follow-up in STEMI patients between BVS and EES.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)